You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Follicular lymphoma

Showing 51 - 75 of 6,008
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Follicular Lymphoma Trial in Boston (Rituximab, Neo Vax, Pembrolizumab)

Recruiting
  • Follicular Lymphoma
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Mar 14, 2022

Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma Trial in United States (Buparlisib, Ibrutinib)

Completed
  • Lymphoma
  • +3 more
  • Basking Ridge, New Jersey
  • +5 more
Oct 7, 2022

Relapsed Follicular Lymphoma, Refractory Follicular Lymphoma Trial in United Kingdom (Epcoritamab, Lenalidomide, Rituximab)

Not yet recruiting
  • Relapsed Follicular Lymphoma
  • Refractory Follicular Lymphoma
  • Aberdeen, United Kingdom
  • +24 more
Apr 28, 2023

Follicular Lymphoma, Relapsed and Refractory Follicular Lymphoma Trial in Guangzhou (Orelabrutinib and Rituximab, Orelabrutinib)

Recruiting
  • Follicular Lymphoma
  • Relapsed and Refractory Follicular Lymphoma
  • Guangzhou, Guangdong, China
  • +2 more
Mar 23, 2022

Recurrent Chronic Lymphocytic Leukemia, Recurrent DLBCL, Recurrent Follicular Lymphoma Trial in Seattle (Nivolumab)

Recruiting
  • Recurrent Chronic Lymphocytic Leukemia
  • +17 more
  • Nivolumab
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Aug 16, 2022

Relapsed/Refractory Marginal Zone Lymphoma Trial in Westbury (Zanubrutinib, Rituximab, Lenalidomide)

Recruiting
  • Relapsed/Refractory Follicular Lymphoma
  • Marginal Zone Lymphoma
  • Westbury, New York
    Clinical Research Alliance, Inc.
Nov 14, 2022

Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma Trial run by the NCI (Obinutuzumab, Venetoclax, Magrolimab)

Recruiting
  • Follicular Lymphoma
  • +4 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 20, 2023

Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia Trial (BGB-21447)

Not yet recruiting
  • Relapsed Non-Hodgkin Lymphoma
  • +6 more
  • (no location specified)
Apr 12, 2023

Grade 3a Follicular Lymphoma, Recurrent Burkitt Lymphoma, Recurrent DLBCL Trial in Atlanta, Columbus (other, drug, biological)

Recruiting
  • Grade 3a Follicular Lymphoma
  • +14 more
  • Laboratory Biomarker Analysis
  • +2 more
  • Atlanta, Georgia
  • +1 more
May 31, 2022

Aggressive B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 3 Follicular

Recruiting
  • Aggressive B-Cell Non-Hodgkin Lymphoma
  • +19 more
  • CD47 Antagonist ALX148
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 9, 2022

Follicular Lymphoma Trial in United States (DRL_RI (Proposed rituximab biosimilar), MabThera®)

Active, not recruiting
  • Follicular Lymphoma
  • DRL_RI (Proposed rituximab biosimilar)
  • MabThera®
  • Whittier, California
  • +3 more
May 27, 2022

Follicular Lymphoma, B-Cell Lymphoma, Mantle Cell Lymphoma Trial in New York (Tazemetostat Pill)

Not yet recruiting
  • Follicular Lymphoma
  • +3 more
  • Tazemetostat Pill
  • New York, New York
    Weill Cornell Medicine/NewYork-Presbyterian Hospital
Jun 28, 2023

Follicular Lymphoma Trial in Toronto (12 Gy in 6 daily fractions)

Recruiting
  • Follicular Lymphoma
  • 12 Gy in 6 daily fractions
  • Toronto, Ontario, Canada
    Sunnybrook Health Sciences Centre
Mar 10, 2022

Ann Arbor Stage I Grade 1 Follicular Lymphoma, Ann Arbor Stage I Grade 2 Follicular Lymphoma, Ann Arbor Stage II Grade 1

Active, not recruiting
  • Ann Arbor Stage I Grade 1 Follicular Lymphoma
  • +9 more
  • Quality-of-Life Assessment
  • +2 more
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Feb 3, 2022

COVID-19 Vaccine and Other Vaccines'-Induced Immune Responses in

Not yet recruiting
  • Follicular Lymphoma
  • Cellular immunity vs SARS-CoV-2
  • +6 more
  • Alessandria, IT, Italy
  • +13 more
Oct 10, 2023

People Living With HIV Treated With CD19-directed CAR T Cell

Active, not recruiting
  • Leukemia
  • +9 more
    • Philadelphia, Pennsylvania
      Pennsylvania Hospital
    Mar 29, 2023

    Follicular Lymphoma Trial in Boston (Lethally Irradiated Lymphoma cells with GM-CSF K562 Cells)

    Active, not recruiting
    • Follicular Lymphoma
    • Lethally Irradiated Lymphoma cells with GM-CSF K562 Cells
    • Boston, Massachusetts
      Dana-Farber Cancer Institute
    Feb 28, 2022

    Follicular Lymphoma Trial in United States (Rituximab, Utomilumab, Avelumab)

    Active, not recruiting
    • Follicular Lymphoma
    • Duarte, California
    • +5 more
    Mar 17, 2022

    Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Marginal Zone Lymphoma, Ann Arbor Stage III Follicular Lymphoma Trial

    Active, not recruiting
    • Ann Arbor Stage II Follicular Lymphoma
    • +9 more
    • Houston, Texas
      M D Anderson Cancer Center
    Feb 3, 2022

    Relmacabtagene Autoleucel in Hematologic Malignancies

    Not yet recruiting
    • Lymphoma, B-Cell
    • +2 more
    • Relmacabtagene Autoleucel
    • Beijing, Beijing, China
    • +1 more
    Nov 15, 2023

    Cardiovascular Events Among Adults Relapsed or Refractory

    Recruiting
    • Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma
    • +9 more
    • Electronic Health Record Review
    • Houston, Texas
      M D Anderson Cancer Center
    Dec 5, 2022

    Follicular Lymphoma and Marginal Zone Lymphoma Trial in Beijing (Recombinant Humanized Monoclonal Antibody MIL62, lenalinomide,

    Recruiting
    • Follicular Lymphoma and Marginal Zone Lymphoma
    • Recombinant Humanized Monoclonal Antibody MIL62, lenalinomide
    • lenalinomide
    • Beijing, China
      Chinese Academy of Medical Sciences and Peking Union Medical Col
    Feb 13, 2022

    Recurrent DLBCL, Recurrent Follicular Lymphoma, Refractory DLBCL Trial in Seattle (Laboratory Biomarker Analysis, Pembrolizumab,

    Active, not recruiting
    • Recurrent Diffuse Large B-Cell Lymphoma
    • +3 more
    • Laboratory Biomarker Analysis
    • +3 more
    • Seattle, Washington
      Fred Hutch/University of Washington Cancer Consortium
    Jul 20, 2022

    DLBCL, Chronic Lymphocytic Leukemia, Follicular Lymphoma Trial in New Haven, Worcester, Dallas (ABBV-319)

    Not yet recruiting
    • Diffuse Large B-Cell Lymphoma
    • +2 more
    • New Haven, Connecticut
    • +2 more
    Aug 22, 2022

    B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Burkitt Lymphoma, Grade 1 Follicular Lymphoma,

    Active, not recruiting
    • B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma
    • +11 more
    • Atlanta, Georgia
    • +1 more
    Apr 18, 2022